Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.

Authors : Lebbé C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dréno B
Year : 2020
Journal : Cancers (Basel)
Volume : 12